New three-gene signature links triaptosis to gastric cancer prognosis

Gastric cancer remains one of the world’s most lethal malignancies, and a new study has added an unexpected twist to the search for better prognostic tools: a recently discovered form of programmed cell death called triaptosis. Researchers in China report that a three-gene signature tied to this endosome-dependent cell death modality can stratify gastric cancer patients into distinct risk groups with markedly different survival outcomes, and that the signature’s activity appears concentrated in fibroblasts within the tumor microenvironment.

Triaptosis is a newly characterized modality of programmed cell death that depends on endosomal function, distinguishing it from apoptosis, necroptosis, and other better-known death pathways. Because triaptosis relies on the lipid kinase VPS34 and endosome-mediated signaling, it intersects with autophagy and endocytosis machinery that tumors frequently co-opt for survival. Its implications for cancer prognosis, however, remained unclear prior to this work.

The research team, led by Xirong Cui and Mao Liu of Neijiang First People’s Hospital, analyzed bulk transcriptomic and clinical data from the TCGA-STAD cohort and the GSE62254 gastric cancer dataset, alongside single-cell RNA sequencing data from GSE183904. They calculated triaptosis-related gene (TRG) scores for each tumor sample using single-sample gene set enrichment analysis, then identified differentially expressed genes between high- and low-TRG-score tumors and between tumor and normal tissue. These candidate genes underwent functional enrichment analysis, Cox proportional hazards regression, and least absolute shrinkage and selection operator (LASSO) regression to construct a prognostic signature that was externally validated in an independent cohort.

The resulting model comprises three genes: ASPN, GRB14, and VTN. ASPN encodes asporin, an extracellular matrix protein previously linked to gastric cancer invasion, migration, and macrophage M2 polarization. GRB14 is an adaptor protein that regulates insulin and growth factor signaling and has been implicated in gastric cancer progression through the PI3K/AKT pathway. VTN encodes vitronectin, a glycoprotein of the extracellular matrix whose overexpression correlates with impaired survival in gastric cancer patients. All three genes showed significantly higher mRNA expression and protein levels in the SGC-7901 gastric cancer cell line than in the non-malignant GES-1 gastric epithelial cell line, verified by reverse transcription-quantitative PCR and Western blotting.

When patients were stratified by the TRG-based risk score, two groups emerged with notably different survival outcomes. High-risk patients exhibited higher stromal scores and distinct immune profiles compared with low-risk patients, with fifteen immune cell types differing significantly between the two groups. The researchers also compared pathway activity, somatic mutation landscapes, tumor mutational burden, and predicted drug sensitivity across risk groups, finding that the signature captured biologically meaningful differences beyond survival statistics alone.

Single-cell RNA sequencing analysis added a cellular dimension to the findings. Fibroblasts and pericytes emerged among the cell types with the highest TRG activity, and the three prognostic genes were significantly overexpressed in fibroblasts. Cell-cell communication analysis revealed that fibroblasts showed enhanced signaling with pericytes in the gastric cancer microenvironment, whereas tumor-derived fibroblasts displayed weaker communication with macrophages, suggesting immune microenvironment remodeling associated with triaptosis activity.

The concentration of the prognostic signal in fibroblasts is particularly intriguing given growing evidence that cancer-associated fibroblasts drive gastric cancer progression, angiogenesis, metastasis, and immunosuppression. Prior work has shown that collagen-rich extracellular matrix produced by these fibroblasts can promote immune evasion through IL4I1-AHR signaling, and that fibroblast heterogeneity shapes the immunosuppressive microenvironment that limits responses to immunotherapy. The new findings suggest that triaptosis-related gene activity in fibroblasts may be a previously unrecognized component of this stromal contribution to prognosis.

The study’s methodology reflects a broader trend in computational oncology: integrating bulk and single-cell transcriptomics with machine learning approaches to extract clinically actionable signatures from public datasets. Similar triaptosis-focused models have recently been constructed for melanoma and hepatocellular carcinoma, indicating that the cancer research community is rapidly probing this novel cell death modality across tumor types. The gastric cancer study distinguishes itself by combining external validation with experimental verification at both the mRNA and protein levels in cell lines.

The authors suggest that the three-gene signature holds potential value for risk stratification and personalized treatment planning in gastric cancer. Because the signature is associated with distinct immune and genomic features, it may eventually help identify patients who could benefit from specific therapeutic strategies, including immunotherapy approaches tailored to the immune microenvironment characteristics of high-risk tumors. The findings also open questions about whether triaptosis pathways in stromal cells could be therapeutically targeted to modify the tumor microenvironment.

Limitations remain, as the signature was developed and validated in retrospective cohorts rather than prospectively, and the experimental verification was confined to cell lines rather than patient tissue. Nonetheless, the study provides a technically rigorous exploration of triaptosis in gastric cancer, linking a novel cell death modality to a stromal-cell-centered prognostic framework. As triaptosis research matures, studies like this one may help clarify whether endosome-dependent cell death pathways represent the next frontier in cancer prognosis and therapy development.

Subject of Research: Exploration and experimental verification of triaptosis-related prognostic genes and cells in gastric cancer

Article Title: Exploration and experimental verification of triaptosis-related prognostic genes and cells in gastric cancer

Article References: Cui, X., Qiu, H., Zhang, H., Xu, H., & Liu, M. (2026). Exploration and experimental verification of triaptosis-related prognostic genes and cells in gastric cancer. Molecular Biology Reports, 53(1), Article 1541. https://doi.org/10.1007/s11033-026-12704-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12704-y

Keywords: Exploration, experimental, verification, triaptosis-related, prognostic, genes, cells, gastric, cancer, scientific research